Our Faculty
David R. Rosenberg, M.D.
Publications of David R. Rosenberg, M.D.
CAP Smart Takes Vol. 20
0.50 CMEs
This volume covers a wide range of topics, from the long-term effects of methylphenidate on sleep in children and adolescents with ADHD, to the cardiac and metabolic safety profile of antipsychotics in youth. It also discusses alternative treatments for treatment-resistant depression in adolescents, such as deep transcranial magnetic stimulation; prescribing tendencies of sleep medication in youth diagnosed with insomnia; and what can be done to improve outcomes for patients diagnosed with early-onset schizophrenia.
CAP Smart Takes Vol. 19
0.50 CMEs
In this volume, we explore topics such as the long-term management of OCD in youth and whether probiotics have a role in managing ADHD symptoms. Are probiotics combined with methylphenidate showing promise?
We also shed light on the controversial use of electroconvulsive therapy (ECT) for adolescents battling severe depression and suicidality. What factors influence its effectiveness? Our exploration continues with noninvasive brain stimulation techniques for neurodevelopmental disorders. How do we ensure their safe application in this population? Lastly, we question the long-term efficacy of escitalopram in adolescents with major depressive disorder (MDD).
CAP Smart Takes Vol. 18
0.50 CMEs
In this volume, we explore various pharmacologic treatments in pediatric psychiatry. We begin with a study on escitalopram's approval for treating children's anxiety disorder and vortioxetine's impact on sleep patterns in adolescents with major depressive disorder (MDD). We also consider the potential of long-acting injectable aripiprazole lauroxil as a safe treatment option for hospitalized teenagers with illnesses like schizophrenia. Lastly, we examine esketamine’s effect on cognitive function in adolescents with MDD and suicidal ideation and assess risperidone's efficacy in treating anorexia nervosa, which unfortunately showed no significant outcome differences.
Tic Disorders in Children and Adolescents – Interview
0.50 CMEs
In this interview, Dr. David Rosenberg discusses treatments for tic disorders in children and adolescents, highlighting the effectiveness of methylphenidate for ADHD and tics, SSRIs and therapy for OCD and tics, and clonazepam for tics with anxiety. The discussion also emphasizes the importance of screening for comorbid psychiatric conditions and considering family history in treatment decisions.
CAP Smart Takes Vol. 17
0.50 CMEs
In this volume, we examine recent studies related to neurodevelopmental disorders, such as the effect of methylphenidate on pain perception thresholds in children with ADHD, the persistence of autism spectrum disorder from early childhood through school age, and the startling increase in pediatric ADHD medication error rates from 2000–21. This volume also includes findings from the COMPASS study regarding the impact of the COVID-19 pandemic on adolescent mental health, particularly on depressive and anxiety symptoms, as well as factors associated with adoption of vaping cessation methods among U.S. adolescents.
CAP Smart Takes Vol. 16
0.50 CMEs
In this volume, we discuss recent studies on ADHD, such as risks related to prenatal exposure to ADHD medication, the safety and efficacy of alpha-2 adrenergic agonists for the treatment of ADHD in preschool children, and the potential link between early childhood anesthesia exposure and subsequent ADHD risk. Additionally, we examine the efficacy and safety of fish oil when used as an adjunctive agent for the treatment of depressive disorders in youth, as well as the risks associated with benzodiazepine use among children with sleep disorders.
CAP Smart Takes Vol. 15
0.50 CMEs
In this volume, we delve into relapse prevention strategies and how the combination of cognitive–behavioral therapy (CBT) and antidepressant continuation can cut the relapse risk for major depressive disorder in youth by roughly 50%. We also discuss the role of antipsychotics in treating youth with anorexia nervosa and the long-term effects of sertraline on pediatric growth and development. How does the association between dissociative effects and the response to ketamine manifest in youth with treatment-resistant depression? Finally, how significant are long-acting injectable antipsychotics in managing schizophrenia spectrum disorders in children and adolescents?
CAP Smart Takes Vol. 14
0.50 CMEs
In this volume, we explore the effects of gender-affirming hormones on the psychosocial functioning in transgender youth, the risk of major malformations following first-trimester exposure to olanzapine, and use of lithium in pediatric bipolar and externalizing disorders. We also tackle 2 articles on ADHD—specifically, how can we better personalize atomoxetine dosage to maximize outcomes for children with ADHD, and what is the safety and tolerability of serdexmethylphenidate/dexmethylphenidate in children with ADHD?
Managing Explosive Behavior in Youth – Interview
0.75 CMEs
In this interview, Dr. David Rosenberg highlights practical considerations regarding the evaluation of children and adolescents with explosive behavior, such as the need to rule out medical conditions and trauma-related disorders. He also reviews essential management strategies for this population, including medication selection and titration, family engagement, and risk management, among others.
CAP Smart Takes Vol. 13
0.50 CMEs
This volume encapsulates crucial aspects of pediatric psychiatric treatment. It begins with a deep dive into managing the adverse effects of antidepressants in youth, followed by an exploration of the impact of age on antidepressant response. It also offers a discussion about a systematic review of the use of lamotrigine in pediatric mood disorders, shedding light on its safety and efficacy. Finally, it aims to address 2 significant queries: What are the suggested strategies for treating ADHD coexisting with anxiety in children, and how are stimulants, atomoxetine, and CBT incorporated into these strategies? Moreover, what are the real-world prescribing patterns and dosage decisions for OROS-methylphenidate?
CAP Smart Takes Vol. 12
0.50 CMEs
In this volume, we explore the potential of N-acetylcysteine (NAC) as an adjunctive therapy for alcohol use disorder in youth and the efficacy of metformin for weight management in youth on antipsychotics. We also address the adverse cognitive effects of chronic cannabis use in this age group, especially among those with ADHD. Additionally, what is the optimal time of day for prescribing long-acting stimulants to youth with ADHD? Lastly, how does combinatorial pharmacogenomic testing hold promise in improving the selection of medications for pediatric patients with mental health disorders, and what are its potential benefits?
Atypical Psychopharmacologic Strategies for Children and Adolescents – Interview
0.75 CMEs
In this interview, Dr. David Rosenberg discusses practical considerations when it comes to atypical psychopharmacologic strategies in children and adolescents and tackles common concerns, such as dosing considerations, possible adverse effects, and tapering strategies. He also addresses questions regarding the use of atypical psychopharmacologic agents for specific clinical concerns, such as insomnia, obsessive-compulsive disorder, and self-injurious behaviors.
1